Terms: = Prostate cancer AND FOXA1, TCF3A, 3169, ENSG00000129514, P55317, HNF3A, MGC33105 AND Prognosis
20 results:
1. Staufen1 Represses the foxa1-Regulated Transcriptome by Destabilizing foxa1 mRNA in Colorectal cancer Cells.
Pasterczyk KR; Li XL; Singh R; Zibitt MS; Hartford CCR; Pongor L; Jenkins LM; Hu Y; Zhao PX; Muys BR; Kumar S; Roper N; Aladjem MI; Pommier Y; Grammatikakis I; Lal A
Mol Cell Biol; 2024; 44(2):43-56. PubMed ID: 38347726
[TBL] [Abstract] [Full Text] [Related]
2. Somatic and Germline Variants Affect prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
3. Determination of TMPRSS2-ERG, SPOP, foxa1, and IDH1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract] [Full Text] [Related]
4. Detection of disease-causing mutations in prostate cancer by NGS sequencing.
Mangolini A; Rocca C; Bassi C; Ippolito C; Negrini M; Dell'Atti L; Lanza G; Gafà R; Bianchi N; Pinton P; Aguiari G
Cell Biol Int; 2022 Jul; 46(7):1047-1061. PubMed ID: 35347810
[TBL] [Abstract] [Full Text] [Related]
5. prognosis Associated With Luminal and Basal Subtypes of Metastatic prostate cancer.
Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
[TBL] [Abstract] [Full Text] [Related]
6. Androgen Signaling in the Tumor Microenvironment.
Özdemir BC
Adv Exp Med Biol; 2021; 1270():169-183. PubMed ID: 33123999
[TBL] [Abstract] [Full Text] [Related]
7. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates foxa1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
8.
Faisal FA; Murali S; Kaur H; Vidotto T; Guedes LB; Salles DC; Kothari V; Tosoian JJ; Han S; Hovelson DH; Hu K; Spratt DE; Baras AS; Tomlins SA; Schaeffer EM; Lotan TL
Clin Cancer Res; 2020 Jun; 26(11):2595-2602. PubMed ID: 31969336
[TBL] [Abstract] [Full Text] [Related]
9. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant prostate cancer.
Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA
Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601
[TBL] [Abstract] [Full Text] [Related]
11. Integrative analysis of cancer driver genes in prostate adenocarcinoma.
Zhao X; Lei Y; Li G; Cheng Y; Yang H; Xie L; Long H; Jiang R
Mol Med Rep; 2019 Apr; 19(4):2707-2715. PubMed ID: 30720096
[TBL] [Abstract] [Full Text] [Related]
12. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant prostate cancer.
Cai L; Tsai YH; Wang P; Wang J; Li D; Fan H; Zhao Y; Bareja R; Lu R; Wilson EM; Sboner A; Whang YE; Zheng D; Parker JS; Earp HS; Wang GG
Mol Cell; 2018 Oct; 72(2):341-354.e6. PubMed ID: 30270106
[TBL] [Abstract] [Full Text] [Related]
13. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Subtypes of prostate cancer.
Arora K; Barbieri CE
Curr Oncol Rep; 2018 Jun; 20(8):58. PubMed ID: 29858674
[TBL] [Abstract] [Full Text] [Related]
15. Transcriptome and Proteome Analyses of TNFAIP8 Knockdown cancer Cells Reveal New Insights into Molecular Determinants of Cell Survival and Tumor Progression.
Day TF; Mewani RR; Starr J; Li X; Chakravarty D; Ressom H; Zou X; Eidelman O; Pollard HB; Srivastava M; Kasid UN
Methods Mol Biol; 2017; 1513():83-100. PubMed ID: 27807832
[TBL] [Abstract] [Full Text] [Related]
16. The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus.
Sakurai K; Reon BJ; Anaya J; Dutta A
Mol Cancer Res; 2015 May; 13(5):828-38. PubMed ID: 25700553
[TBL] [Abstract] [Full Text] [Related]
17. Androgen receptor-independent function of foxa1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract] [Full Text] [Related]
18. cancer genetics and genomics of human FOX family genes.
Katoh M; Igarashi M; Fukuda H; Nakagama H; Katoh M
Cancer Lett; 2013 Jan; 328(2):198-206. PubMed ID: 23022474
[TBL] [Abstract] [Full Text] [Related]
19. foxa1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
Gerhardt J; Montani M; Wild P; Beer M; Huber F; Hermanns T; Müntener M; Kristiansen G
Am J Pathol; 2012 Feb; 180(2):848-61. PubMed ID: 22138582
[TBL] [Abstract] [Full Text] [Related]
20. Dual role of foxa1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
[TBL] [Abstract] [Full Text] [Related]
